Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
SenzaGen AB
SenzaGen AB
Activities:
Regulatory
Analysis
Pharmaceutical
X
LinkedIn
Trending Articles
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Fasenra for EGPA: addressing unmet needs
Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities
Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Research & Development
SenzaGen and MB Research Labs sign toxicology agreement
With new legislature, animal-free <em>in vitro</em> toxicological testing is a growing market in the US. This collaboration taps into this market
Analysis
Next-generation safety testing
In vitro genetic testing offers an ethical alternative to animal testing, which is also cheaper, faster and more reliable
Pharmaceutical
Swedish SenzaGen teams up with Chinese animal-free testing specialist
The partnership comes at a time when a ban on animal experiments is expected
SenzaGen strengthens its organisation with IR and communications director
Recruitment
SenzaGen recruits Business Development Director
Research & Development
Collaboration tackles respiratory irritancy hazard
SenzaGen and AstraZeneca will develop a new genomic signature to distinguish allergens from irritants in the respiratory tract
Subscribe now